Researchers investigated how drug treatment affects signal carriers in diabetic retinas, finding half of proteins normalized by metformin treatment. However, other essential proteins remained unchanged despite improved blood glucose levels, suggesting a need for further combination therapies to effectively treat diabetic retinopathy.
Adults with ADHD frequently experience significant psychosocial impairments due to persistent symptoms. Current guidelines recommend a multimodal treatment approach, including pharmacotherapy, psycho-education, and occupational rehabilitation.
Researchers argue that exercise should be considered alongside drug therapy due to its well-documented health benefits. However, the current evidence base is limited, with only a small amount of trial data available on the mortality benefits of exercise compared to drugs.
Researchers found that mild hypothermia improved behavioral scores and increased surviving neurons in rats with TBI. The treatment also reduced harmful protein levels linked to brain injury and cognitive dysfunction.
The NIH's Therapeutics for Rare and Neglected Diseases program aims to develop treatments for rare diseases affecting fewer than 200,000 Americans. Four new pre-clinical projects target retinitis pigmentosa, hypoparathyroidism and LEOPARD syndrome, marking the first use of stem cells and collaboration with Eli Lilly.
A preclinical study found that VBP15 decreases inflammation in mice with symptoms similar to those found in patients with Duchenne muscular dystrophy. The drug protects and strengthens muscle without the side effects linked to current treatments.
Researchers at Cardiff University have made a breakthrough in treating acute pancreatitis by reducing calcium flow into pancreatic cells, stopping the root cause of the disease. The study shows promise for developing an effective treatment for this often fatal disease.
A global study has found that many patients don't know they have hypertension and, even if they do, too few are receiving adequate drug therapy for their hypertension. The study found 46.5% of those with hypertension were aware of the diagnosis, while blood pressure was controlled among 32.5% of those being treated.
A multinational study of over 140,000 participants from 17 countries found a significant gap in hypertension detection and control, with only half aware of their diagnosis and one-third being treated effectively. The study highlights the need for substantial improvement in hypertension diagnosis and treatment.
Researchers at ETH Zurich discovered that IL-7 enhances lymphatic vessel drainage, a crucial function that could improve lymphedema treatment outcomes. This finding may help prevent or alleviate fluid accumulation and tissue swelling in patients with compromised lymphatic systems.
Researchers found that generic substitutions result in $127-$160 annual savings, while therapeutic substitutions yield $389-$452 per beneficiary. Therapeutic substitutions have the potential to double or triple annual cost savings compared to generic substitutions.
A US model of collaborative care for depression has been shown to improve symptoms immediately after treatment. After 12 months, 15% more patients remained improved compared to those who saw their GP alone.
A new MR analysis technique called vessel architectural imaging (VAI) can identify changes in brain tumor blood vessels within days of anti-angiogenesis therapy initiation. VAI has shown that 10 out of 30 patients with recurrent glioblastoma responded to the treatment, surviving six months longer than non-responders.
Researchers found that distracting similarities in testimonials can result in less medically appropriate treatment recommendations. They suggest consumers recognize the potential for 'gut feel' decisions based on credibility rather than accurate data.
Researchers have discovered that L-3-n-butylphthalide can improve cognitive function and protect nerve cells in animal models of vascular dementia. The compound has been shown to activate the Akt kinase pathway, suggesting its potential as a new treatment option for vascular dementia.
A new study published in JAMA found that treating post-traumatic stress disorder (PTSD) and alcohol dependence simultaneously does not lead to increased drinking, but rather improves treatment outcomes. Prolonged exposure therapy combined with naltrexone reduced cravings and drinking days, even after treatment stopped.
A study found that naltrexone treatment reduced the percentage of days drinking among patients with posttraumatic stress disorder (PTSD) and alcohol dependence. The combination of prolonged exposure therapy and naltrexone did not increase drinking or alcohol craving, contradicting common views.
The Donald Pinkel Endowed Chair supports the hospital's CEO, Dr. William E. Evans, in his research and academic programs. This endowment honors St. Jude's first director, who developed a revolutionary approach to treating childhood cancer.
Rapamycin treatment improved memory, reduced thyroid follicle size, and decreased cancer rates in older mice. However, its effects were age-independent, with similar benefits seen in young mice, suggesting a potential use for relieving some age-related conditions.
A new research project from Aarhus University found that test-tube children are generally as mentally healthy as naturally conceived children. However, children born to mothers who received hormone stimulation treatment for infertility have a small but increased risk of developing mental disorders such as autism or ADHD.
Israel's unique blend of medical innovation, universal accessibility and patient compliance leads to significant reduction in preventable blindness rates. The country's success in preventing avoidable blindness has emerged as a world leader, making it an attractive model for other nations.
A new treatment approach using MGN1703, a small DNA molecule that stimulates the immune system, has shown promise in prolonging progression-free survival in patients with metastatic colorectal cancer. The drug is designed to broadly activate all components of the innate immune system to destroy cancer cells.
A study found that biological tumor necrosis factor inhibitors did not significantly reduce work loss compared to conventional treatment in patients with early rheumatoid arthritis. Early and aggressive treatment can help reverse increasing work loss days, but the cost of infliximab outweighs its benefits.
The latest IST-3 results show that alteplase treatment significantly improves mobility, self-care, and overall quality of life in stroke survivors. At 18 months, patients treated with alteplase had a 28% greater odds of being alive and independent compared to those not receiving the drug.
A study found specific patterns of brain activity can indicate whether a patient will respond to medication or psychotherapy for depression. Low activity in the anterior insula region was associated with remission through CBT, while high activity was linked to improved response to medication.
Researchers at The Mount Sinai Medical Center found that commonly prescribed medications can either block or enhance beta-amyloid accumulation in the brain. Treatment with certain drugs has been shown to significantly reduce amyloid plaques and neurodegeneration in mice.
A new software toolkit combines deformable anthropomorphic models with precision dosimetry to determine the most effective cancer-killing dose for every patient. This approach enables personalized radionuclide drug therapies, leading to improved outcomes and better survival rates.
Researchers at the University of Guelph have discovered a liver enzyme that protects cells from bilirubin damage, paving the way for new treatments for jaundice. The enzyme helps remove bilirubin and prevent liver cell death, offering hope for alternative therapies.
Researchers found that rapamycin improved cardiac function and reduced inflammation in aged mice, slowing down heart dysfunction. The study suggests potential benefits for humans with heart disease, as it is already FDA-approved for other indications.
Researchers found that consistent bedtime within 45 minutes increases likelihood of using CPAP for at least four hours. Adults with inconsistent bedtimes are more likely to nonadhere to treatment, increasing odds by 3.2 times.
Theoretical mathematical models can help analyze viral dynamics in the early phase following exposure to HIV, providing insights into therapeutic and prevention strategies. The models suggest that reverse transcriptase inhibitors are more effective than protease inhibitors for PrEP, while fast initiation of treatment is crucial for PEP.
A new experimental iPhone application has been shown to transmit diagnostic heart images faster and with greater reliability than current methods. The app could help save lives by speeding treatment for STEMI, the deadliest type of heart attack.
IDIBELL has licensed a patent for a repositioned drug to treat X-linked adrenoleukodystrophy, a rare neurodegenerative disease. The patented product has shown promise in laboratory studies, but further research is needed before its application can be considered.
Researchers at the University of Illinois have developed a small molecule that breaks up protein-RNA clusters causing muscular dystrophy, offering hope for treatment. The compound targets only the repeating RNA sequence, increasing regulatory activity and breaking up disease-causing clusters.
The European Society of Cardiology recommends catheter-based renal denervation for patients with resistant hypertension, indicating its potential in treating multiple cardiovascular diseases. The technique involves radiofrequency ablation to reset renal blood pressure regulation and reduce whole-body sympathetic nerve activity.
The increasing cost of leukemia treatments in the US is leaving many patients under- or untreated due to unaffordable care. CML experts call for a long-term solution to manage treatment costs, balancing investments from various parties.
A retrospective study suggests that patients with lung cancer carrying specific HER2 mutations may experience tumor shrinkage and delayed disease progression when treated with anti-HER2 drugs. The study found 1.7% of NSCLC patients in Europe had these rare mutations, which can lead to continuous activation of the HER2 protein.
Researchers discovered that nalmefene significantly reduces alcohol consumption and improves patients' clinical status and liver enzymes. The medication is well-tolerated with mild to moderate side effects.
Researchers at the University of Manchester have made a breakthrough in developing an effective treatment for neurodegenerative diseases. They identified the molecular structure of the enzyme kynurenine 3-monooxygense (KMO) and discovered a compound that can inhibit its activity.
Researchers have developed nanoparticles that improve siRNA delivery, enabling more efficient silencing of specific genes. The approach shows promise in addressing the challenge of targeted delivery for gene therapies.
A study published in Diabetologia found that only 10% of diabetes trials focus on prevention or behavioral therapies. Most trials are small to medium-sized and prioritize drug treatments over preventive measures. The analysis highlights the need for more research addressing the needs of diverse populations affected by diabetes.
Researchers developed biodegradable nanoparticles that deliver inflammation-resolving drugs to sites of tissue injury, promoting clearance of pathogens or damaged tissue and restoring normal state. The treatment has potential for treating conditions like atherosclerosis and neurodegenerative diseases.
Researchers are developing tiny sensory implants that can measure vital tumor factors, enabling doctors to target radiotherapy and chemotherapy for more effective treatment. The devices aim to personalize therapy based on individual patient responses, improving recovery chances.
Researchers have mapped tapeworm genomes to identify potential drug targets using existing drugs, which could lead to faster and more effective treatments. The discovery has significant implications for the development of urgently needed therapies for these devastating diseases.
Researchers have developed an algorithm that can explain how traditional medicinal compounds work in the body, bridging the gap between Western and traditional medicine. This breakthrough may lead to more effective treatments for various diseases.
Researchers at Mount Sinai are studying spasmodic dysphonia, a neurological disorder characterized by vocal cord spasms. The team aims to identify new drug targets and diagnostic biomarkers using advanced neuroimaging methodologies.
A new study found that adrenocorticotropic hormone (ACTH) may be effective in treating people with breakthrough multiple sclerosis. Participants who received ACTH had fewer relapses and no psychiatric side effects, compared to those receiving methylprednisolone.
The European League Against Rheumatism recommends immediate use of synthetic DMARDs after diagnosis, but they are expensive. The survey found that 26 countries cannot afford biological DMARDs, excluding 320 million people from treatment.
Researchers identified a molecule called lipoxin A4 that plays a crucial role in resolving airway inflammation in asthma. This discovery provides new direction for developing next-generation asthma therapies to decrease chronic inflammation.
Researchers at Case Western Reserve University have validated a questionnaire to assess youth participation in Alcoholics Anonymous (AA)-related helping activities. The Service to Others in Sobriety (SOS) questionnaire shows promise in identifying youths at risk of relapse and promoting recovery.
A pilot study shows that qigong therapy significantly reduced cocaine cravings and depression symptoms in individuals undergoing residential substance abuse treatment. This promising treatment approach may have profound consequences in drug rehabilitation programs.
A preclinical study uses ultrasonic molecular imaging and Dynamic Contrast Enhanced-Perfusion Imaging to measure response to pancreatic cancer therapy. The study reveals that these new technologies can detect molecular signs of tumor response after just 2 days, improving the early identification of therapeutic response.
Patients with spinal stenosis who receive steroid injections show less improvement in pain and physical functioning, regardless of whether they undergo surgery. The study suggests that ESI may cause worsening of spinal narrowing or nerve impingement, leading to more complicated surgeries.
A new enzyme therapy has significantly delayed the onset and progression of symptoms in dogs with Batten disease, a rare genetic disorder affecting children. The treatment, developed by MU and BioMarin researchers, replaces the deficient enzyme and is administered into the spinal fluid, slowing brain degeneration and extending survival.
A recent study published in Cell Reports found that sunitinib, an anticancer drug, does not cause lingering risks for patients after their treatment ends. The research suggests that sunitinib works by slowing tumor growth and prolonging survival during treatment, without altering tumor biology after the drug is stopped.
A pair of commentaries highlight a public health debate surrounding CDC treatment guidelines for exposed individuals during the 2012 fungal meningitis outbreak. The American Society for Microbiology has published two commentaries questioning and defending the CDC's recommendations.
Researchers from Arunachal Pradesh and the Research Institute of World's Ancient Traditions Cultures and Heritage successfully isolated dormant TB bacteria from CD271+ stem cells in bone marrow. The study provides evidence that TB bacteria hide in these stem cells to escape drug treatment, making it difficult to eradicate the disease.
A new enzyme treatment has been developed to neutralize the effects of lethal chemicals responsible for thousands of deaths each year. The treatment, known as a bioscavenger, was found to protect mice against nerve agents and showed no lasting effects.
A new study from the University of Pennsylvania School of Medicine found that black and Hispanic patients are less likely to complete substance abuse treatment programs compared to white patients. The study suggests that socioeconomic factors, such as unemployment and housing instability, contribute to these disparities.
A new NIH-funded study shows that inexpensive education efforts can increase safe use of clot-busting drug tPA at local hospitals, improving stroke care. Community hospitals across Michigan saw a significant improvement in tPA use rates after receiving educational support and round-the-clock treatment assistance.